Clinical Trials
3 trialsNCT01782976 2018-01-19
Ph II Cilengitide Plus Bevacizumab for Recurrent Glioblastoma (GBM)
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT01517776 2015-07-21
HGG-CilMetro
Martin-Luther-Universität Halle-Wittenberg
Phase 2 Terminated
NCT00705016 2014-04-30
ADVANTAGE
Merck KGaA, Darmstadt, Germany
Phase 1/2 Completed